Momenta Pharmaceuticals, Inc. (MNTA)

[urche]

Dew,
Thanks for your candid response to Biopearl's pointed questions. My sense is similar to yours, that no matter what happens to the share price tomorrow, the effect is likely to be short-lived and the patent trial loss does little to affect long term (2-3 yr) value. So, I think the answer to Biopearl's question about whether to sell MNTA at this point depends entirely on one's time horizon as an investor. Short term traders will sell because of the perception that this stock will flounder for many months, and long term traders are likely to see a buying opportunity if they think the market overreacts. I say this adverse legal outcome was priced in.

Urche